Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys.
Efficacious interventions are urgently needed for the treatment of COVID-19. Here, we report a monoclonal antibody (mAb), MW05, with SARS-CoV-2 neutralizing activity by disrupting the interaction of receptor binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) receptor. Crosslinking of Fc with Fc?RIIB mediates antibody-dependent enhancement (ADE) activity by MW05. This ... activity is eliminated by introducing the LALA mutation to the Fc region (MW05/LALA). Potent prophylactic and therapeutic effects against SARS-CoV-2 are observed in rhesus monkeys. A single dose of MW05/LALA blocks infection of SARS-CoV-2 in prophylactic treatment and clears SARS-CoV-2 in three days in a therapeutic treatment setting. These results pave the way for the development of MW05/LALA as an antiviral strategy for COVID-19.
Mesh Terms:
Angiotensin-Converting Enzyme 2, Animals, Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, Antiviral Agents, Betacoronavirus, COVID-19, Cell Line, Chlorocebus aethiops, Coronavirus Infections, Female, HEK293 Cells, Humans, Macaca mulatta, Male, Pandemics, Peptidyl-Dipeptidase A, Pneumonia, Viral, Receptors, IgG, Receptors, Virus, SARS-CoV-2, Spike Glycoprotein, Coronavirus, Vero Cells, Virus Attachment
Angiotensin-Converting Enzyme 2, Animals, Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, Antiviral Agents, Betacoronavirus, COVID-19, Cell Line, Chlorocebus aethiops, Coronavirus Infections, Female, HEK293 Cells, Humans, Macaca mulatta, Male, Pandemics, Peptidyl-Dipeptidase A, Pneumonia, Viral, Receptors, IgG, Receptors, Virus, SARS-CoV-2, Spike Glycoprotein, Coronavirus, Vero Cells, Virus Attachment
Nat Commun
Date: Nov. 13, 2020
PubMed ID: 33188207
View in: Pubmed Google Scholar
Download Curated Data For This Publication
245629
Switch View:
- Interactions 2